gemcitabine ,oxaliplatin,anlotinib,Sintilimab

Phase 2Monoclonal antibody

gemcitabine ,oxaliplatin,anlotinib,Sintilimab is one of 6 small molecule programs targeting Sintilimab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SintilimabNot yet recruiting

SintilimabPhase 2

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Sintilimab

#DrugCompanyPhaseTrials

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

12 2

Lenvima

Eisai

Phase 3

2 3

Experimental Drug

MMedesis Pharma SA

Phase 3

1 4

Sintilimab Plus Chemotherapy

FFudan University

Phase 2

1 5

gemcitabine ,oxaliplatin,anlotinib,Sintilimab

SSichuan University

Phase 2

1 6

Sintilimab Combined With Anlotinib

ZZhejiang Cancer Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sintilimab1 trial

Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Not yet recruiting·SSichuan University·Phase 1/2·NCT06033118·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for gemcitabine ,oxaliplatin,anlotinib,Sintilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine ,oxaliplatin,anlotinib,Sintilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine ,oxaliplatin,anlotinib,Sintilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SSichuan University

gemcitabine ,oxaliplatin,anlotinib,Sintilimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sintilimab1 trial

References

Drug Info

Quick Facts

Related News